Sleep Apnea Pathophysiology

Sleep apnea is not merely loud snoring; it is a serious sleep disorder characterized by repeated breathing interruptions during sleep. Understanding its pathophysiology is crucial for you as a future clinician because it is highly prevalent, often undiagnosed, and directly linked to significant morbidity, including cardiovascular disease and impaired daytime function.

The Mechanism of Obstructive Sleep Apnea: Airway Collapse

Obstructive sleep apnea (OSA) is fundamentally a mechanical problem. During sleep, particularly in the rapid eye movement (REM) stage, muscle tone throughout the body decreases. This includes the muscles of the upper airway—the soft palate, tongue, and pharyngeal walls. In susceptible individuals, this loss of tone allows the airway to collapse or become obstructed, blocking airflow despite ongoing respiratory effort from the diaphragm and chest muscles.

Each obstructive event, which can last from 10 seconds to over a minute, results in intermittent hypoxia, a cycle of dropping blood oxygen levels. The brain detects this hypoxia and rising carbon dioxide, triggering a micro-arousal—a brief awakening that restores muscle tone and opens the airway. Breathing resumes, often with a gasp or snort, before the cycle repeats, sometimes hundreds of times per night. Consider a patient vignette: a 45-year-old man with obesity presents with excessive daytime sleepiness. His bed partner reports loud, interrupted snoring. This classic history points to the repeated collapse and reopening of his airway, fragmenting his sleep architecture and causing the hypoxia that drives long-term complications.

The Neurological Basis of Central Sleep Apnea

In contrast, central sleep apnea (CSA) originates from a failure of central command. Here, the problem is not a blocked airway but a temporary lack of respiratory effort. CSA results from a decreased central respiratory drive, where the brainstem's respiratory centers fail to send the appropriate signals to the breathing muscles. This can occur due to conditions like heart failure, stroke, or opioid use, which disrupt the delicate feedback loops controlling ventilation.

During a central event, there is no effort to breathe: the chest and abdomen are still. Like OSA, this leads to intermittent hypoxia and subsequent arousals, but the initiating defect is neurological. It is critical to distinguish between these types, as their management differs fundamentally. For instance, a patient with severe heart failure may develop Cheyne-Stokes respiration—a form of CSA with a crescendo-decrescendo pattern of breathing—due to delayed circulation time affecting chemoreceptor feedback, not due to any physical airway obstruction.

Risk Factors and Systemic Consequences

The pathophysiology of sleep apnea does not occur in a vacuum; specific anatomical and physiological predispositions increase risk. For OSA, the primary risk factors are often structural. Obesity leads to fatty infiltration in the soft tissues of the neck, directly narrowing the pharyngeal airway. A large neck circumference (greater than 17 inches in men or 16 inches in women) is a strong clinical predictor. Craniofacial abnormalities, such as retrognathia (a receding chin) or a low-lying soft palate, can also reduce airway size and promote collapse.

The consequences of repeated nocturnal events are systemic. Daytime somnolence is a direct result of sleep fragmentation from constant arousals, impairing cognitive function and increasing accident risk. More insidiously, the cycles of intermittent hypoxia and reoxygenation create oxidative stress and sympathetic nervous system activation. This leads to endothelial dysfunction, systemic inflammation, and increased hypertension. Over time, this contributes to a heightened risk for cardiovascular disease, including arrhythmias, heart failure, coronary artery disease, and stroke. The pathophysiological cascade turns a nocturnal breathing disorder into a major cardiometabolic threat.

Diagnostic Assessment: Polysomnography

Given that symptoms like snoring and fatigue are common but non-specific, objective testing is essential. The gold-standard diagnosis for both OSA and CSA is overnight polysomnography (a sleep study). This comprehensive test simultaneously records multiple physiological parameters: brain waves (EEG) to stage sleep, eye movements (EOG), muscle activity (EMG), heart rhythm (ECG), airflow at the nose and mouth, respiratory effort, and blood oxygen saturation (pulse oximetry).

Polysomnography allows clinicians to precisely quantify events. An apnea is a complete cessation of airflow for ≥10 seconds. A hypopnea is a reduction in airflow associated with a drop in oxygen saturation or an arousal. The Apnea-Hypopnea Index (AHI)—the number of apneas and hypopneas per hour of sleep—is used to classify severity. Crucially, polysomnography distinguishes obstructive events (where respiratory effort continues) from central events (where effort is absent), guiding appropriate therapy. Home sleep apnea tests are sometimes used for uncomplicated OSA suspicion, but in-lab polysomnography remains definitive, especially for suspected CSA or complex cases.

Treatment Strategies for Obstructive Sleep Apnea

Management targets the underlying pathophysiology. For OSA, the first-line and most effective treatment is continuous positive airway pressure (CPAP). During sleep, a CPAP machine delivers a constant stream of pressurized air through a mask, acting as a pneumatic splint to hold the upper airway open. This prevents collapse, eliminates apneas, and resolves intermittent hypoxia. Consistent use improves symptoms and mitigates cardiovascular risks.

A foundational adjunctive therapy is weight loss. For patients with obesity, even a 10% reduction in body weight can significantly lower the AHI by reducing parapharyngeal fat deposition and improving lung volumes. Other treatments address anatomical contributors: oral appliances that advance the jaw can be used for mild-to-moderate OSA, and surgical options (like uvulopalatopharyngoplasty or maxillomandibular advancement) aim to physically enlarge the airway. For CSA, treatment focuses on the underlying cause, such optimizing heart failure management, or using adaptive servo-ventilation (ASV) devices that support breathing in a more complex, variable pattern.

Common Pitfalls

Pitfall 1: Attributing All Sleep Apnea to Obstruction. A 68-year-old man with a history of atrial fibrillation and heart failure is assumed to have OSA due to his snoring. However, his sleep study reveals primarily central apneas. Correction: Always review the raw polysomnography data to distinguish between obstructive and central events. Treating CSA with standard CPAP may be ineffective or even harmful; the correct approach involves addressing the cardiogenic cause or using a ventilator designed for CSA.

Pitfall 2: Focusing Solely on Daytime Sleepiness. A patient's excessive sleepiness improves with CPAP, so follow-up is neglected. Correction: The cardiovascular and metabolic risks of sleep apnea require ongoing management. You must monitor for and manage associated hypertension and encourage cardiovascular risk reduction, as the disease has systemic effects beyond fatigue.

Pitfall 3: Accepting Poor CPAP Adherence at Face Value. A patient reports they "can't tolerate" their CPAP machine. The clinician does not investigate further and labels them non-adherent. Correction: Poor adherence is often a treatable problem. Explore specific barriers: mask discomfort, nasal congestion, or claustrophobia. Solutions include mask refitting, adding heated humidification, or using a ramp feature that slowly increases pressure. Engaging the patient in problem-solving is key to successful long-term therapy.

Summary

• Obstructive sleep apnea (OSA) is caused by physical collapse of the upper airway during sleep, leading to cycles of intermittent hypoxia and micro-arousals that fragment sleep.
• Central sleep apnea (CSA) stems from a decreased central respiratory drive, where the brain fails to signal the muscles to breathe, despite an open airway.
• Key risk factors for OSA include obesity, large neck circumference, and craniofacial abnormalities, which anatomically predispose the airway to collapse.
• The disorder causes daytime somnolence and, via oxidative stress and sympathetic activation, contributes to hypertension and cardiovascular disease.
• Definitive diagnosis requires polysomnography, which quantifies events and distinguishes between obstructive and central types.
• First-line treatment for OSA involves CPAP therapy to pneumatically splint the airway open, supplemented by weight loss and other interventions targeting anatomical contributors.